RecruitingNCT07036718
NIS PDC the Efficacy and Safety of Iptacopan in Adults in Routine Clinical Practice
A Prospective, Non-interventional Study to Evaluate the Efficacy and Safety of Iptacopan in Adults With Paroxysmal Nocturnal Hemoglobinuria (PNH) in Routine Clinical Practice in the Russian Federation
Sponsor
Novartis Pharmaceuticals
Enrollment
100 participants
Start Date
Jul 28, 2025
Study Type
OBSERVATIONAL
Summary
This is a prospective, non-interventional, multicenter study to evaluate the efficacy and safety of iptacopan in patients with PNH in real-world settings in Russia.
Eligibility
Min Age: 18 Years
Inclusion Criteria4
- Age ≥18 years at the start of iptacopan therapy.
- The patient is undergoing treatment with iptacopan.
- The treating physician decided to prescribe iptacopan based on the Summary of Product Characteristics during routine clinical practice, regardless of study participation.
- Provision of written informed consent.
Exclusion Criteria1
- \. Any situations where iptacopan is contraindicated in accordance with the Summary of Product Characteristics.
Interested in this trial?
Get notified about updates and connect with the research team.
Locations(8)
View Full Details on ClinicalTrials.gov
For the most up-to-date information, visit the official listing.
NCT07036718